更昔洛韦与单磷酸阿糖腺苷治疗小儿传染性单核细胞增多症的疗效对比

Efficacy comparison of ganciclovir and vidarabine monophosphate in the treatment of infectious mononucleosis in children

目的分析更昔洛韦与单磷酸阿糖腺苷治疗小儿传染性单核细胞增多症(IM)的临床疗效。方法80例IM患儿,按照入院先后顺序分为对照组和观察组,每组40例。对照组患儿采取单磷酸阿糖腺苷治疗,观察组患儿采取更昔洛韦治疗。比较两组患儿治疗效果、症状改善时间及不良反应发生情况。结果观察组患儿治疗总有效率为97.50%,明显高于对照组的70.00%,差异有统计学意义(P<0.05)。治疗后,观察组患儿淋巴结肿大消退时间(6.30±1.50)d、退热时间(2.80±0.80)d、咽痛恢复时间(4.20±0.80)d、肝脾肿大消失时间(6.50±1.50)d、住院时间(8.50±1.50)d,均明显短于对照组的(8.80±2.20)、(3.80±1.20)、(5.50±1.20)、(8.30±1.80)、(11.50±2.50)d,差异有统计学意义(P<0.05)。两组患儿用药后均无明显不良反应,用药安全性理想。结论与单磷酸阿糖腺苷治疗比较,更昔洛韦治疗小儿IM效果更为理想,可加速改善患儿症状体征,安全性好。

Objective To analyze the clinical efficacy of ganciclovir and vidarabine monophosphate in the treatment of infectious mononucleosis(IM)in children.Methods A total of 80 children with IM were divided into a control group and an observation group according to the order of admission,with 40 cases in each group.Children in the control group were treated with vidarabine monophosphate,and children in the observation group were treated with ganciclovir.The therapeutic effect,symptom improvement time,and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 97.50%,which was significantly higher than 70.00%in the control group,and the difference was statistically significant(P<0.05).After treatment,the regression time of enlarged lymph nodes(6.30±1.50)d,fever clearance time(2.80±0.80)d,recovery time of sore throat(4.20±0.80)d,disappearance time of hepatosplenomegaly(6.50±1.50)d,and hospitalization time(8.50±1.50)d in the observation group were significantly shorter than(8.80±2.20),(3.80±1.20),(5.50±1.20),(8.30±1.80),and(11.50±2.50)d in the control group,and the differences were statistically significant(P<0.05).There were no obvious adverse reactions in the two groups of children after medication,and the medication safety was ideal.Conclusion Compared with the treatment of vidarabine monophosphate,ganciclovir is more effective in the treatment of children with IM,and can accelerate the improvement of symptoms and signs in children with high safety.